Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28936084 | 0.87 | CYP1A2 (0.54) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL6443298 | 0.85 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL1321228 | 0.84 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL729692 | 0.84 | ALDH1A1 (0.61) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL6910495 | 0.84 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL6406854 | 0.84 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL30924172 | 0.84 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL487508 | 0.84 | ALDH1A1 (0.61) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL2001872 | 0.84 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 | |
| SCHEMBL28936085 | 0.82 | CYP1A2 (0.54) | SLC1A3SLC1A2SLC1A1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370751-B2 | Sulfonium salt, heat- or photo-acid generator, heat- or photo-curable composition, and cured product thereof | SAN APRO LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| CN-109661601-B | Polarizing plate and method for manufacturing same | 住友化学株式会社 | 2022-02-01 | — | — | CN | disclosed |
| CN-109311915-B | Sulfonium salt, thermal or photoacid generator, thermal or photocurable composition, and cured product thereof | 三亚普罗股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20190284134-A1 | SULFONIUM SALT, HEAT- OR PHOTO-ACID GENERATOR, HEAT- OR PHOTO-CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | SAN APRO LTD. (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3492476-A1 | SULFONIUM SALT, HEAT- OR PHOTO-ACID GENERATOR, HEAT-CURABLE OR PHOTOCURABLE COMPOSITION, AND CURED PRODUCT THEREOF | San-Apro Ltd. (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-9884882-B2 | Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate | FUJIFILM CORPORATION (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-3109245-B1 | METHOD FOR PRODUCTING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE | FUJIFILM CORP (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-3109245-A1 | METHOD FOR PRODUCTING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE | FUJIFILM Corporation (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20160355536-A1 | METHOD FOR PRODUCING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE | FUJIFILM CORPORATION (JP) | 2016-12-08 | — | — | US | disclosed |
| EP-2497475-A1 | Treatment of laminitis with platelet aggregation inhibitors | Dussler, Sabine (DE) | 2012-09-12 | — | — | EP | disclosed |
| EP-0542411-B1 | TETRAHYDROTHIENOPYRIDINE DERIVATIVES, FURO AND PYRROLO ANALOGS THEREOF AND THEIR PREPARATION AND USES FOR INHIBITING BLOOD PLATELET AGGREGATION | SANKYO CO (JP) | 1998-08-12 | — | — | EP | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5436242-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation | SANKYO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5288726-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | UBE INDUSTRIES LIMITED (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0542411-A2 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | Sankyo Company Limited (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284134-A1 | SULFONIUM SALT, HEAT- OR PHOTO-ACID GENERATOR, HEAT- OR PHOTO-CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | TST, MPST, ASIC1 | SLC1A3 1585/4885SLC1A2 2012/4885SLC1A1 1386/4885 |
| US-11370751-B2 | Sulfonium salt, heat- or photo-acid generator, heat- or photo-curable composition, and cured product thereof | TST, MPST, ASIC1 | SLC1A3 1585/4885SLC1A2 2012/4885SLC1A1 1386/4885 |
| US-20160355536-A1 | METHOD FOR PRODUCING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE | ST6GAL1, FUT6, FUT5 | SLC1A3 1421/4885SLC1A2 1227/4885SLC1A1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.